Formulation development and evaluation of controlled porosity osmotic pump delivery system for oral delivery of atenolol

Main Article Content

Garvendra S Rathore
RN Gupta


In the present study, we developed and evaluated the controlled porosity osmotic pump (CPOP) based drug deliverysystem of sparingly water soluble drug atenolol (ATL).We selected target release profile and optimized different variables
to help us achieve this. Formulation variables, such as, the levels of solubility enhancer (0-15% w/w of drug), ratio of the drug to the osmogents, coat thickness of the semipermeable membrane (SPM) and level of pore former (0-20% w/w of polymer) were found to effect the drug release from the developed formulations. Cellulose acetate (CA 398-10) was used as
the semipermeable membrane containing polyethylene glycol 400 as the Cplasticizer. ATL release was directly proportional to the level of the solubility enhancer, osmotic pressure generated by osmotic agent and level of pore former; however, was inversely proportional to the coat thickness of SPM. Drug release from developed formulations was independent of the pH and agitation intensities of release media. Burst strength of the exhausted shells decreased with increase in the level of pore former. The optimized formulations were subjected to stability studies as per International Conference on Harmonisation (ICH) guidelines, and formulations were found to be stable after 3 months study. Steady-state plasma levels of drug were predicted by the method of superposition.


Download data is not yet available.

Article Details

How to Cite
Rathore, G. S., & Gupta, R. (2014). Formulation development and evaluation of controlled porosity osmotic pump delivery system for oral delivery of atenolol. Asian Journal of Pharmaceutics (AJP), 6(2).


Khan MA, Bolton S, Kislalioglu MS. Optimization of process variables

for the preparation of ibuprofen coprecipitates with Eudragit S100. Int

J Pharm 1994;102:185-91.

Khan MA, Karnachi AA, Singh SK, Sastry SV, Kislalioglu SM,

BoRon S. Controlled release coprecipitates: Formulation considerations.

J Control Release 1995;37:132-41.

Singh SK, Dodge J, Durrani MJ, Khan MA. Optimization and

characterization of controlled release pellets coated with an

experimental latex: I. Anionic drug. Int J Pharm 1995;125:243-55.

Jonkman JH. Food Interactions with Sustained-Release Theophylline

Preparations 1: A Review. Clin Pharmacokinet 1989;16:162-79.

Santus G, Baker WR. Osmotic drug delivery: A review of the patent

literature. J Control Release 1995;35:1-21.

Verma RK, Garg S. Current status of drug delivery technologies and

future direction. Pharm Tech 2001;25:1-14.

Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery.

Drug Dev lnd Pharm 2000;26:695-708.

Chao ST, Prather D, Pinson D, Coen P, Pruitt B, Knowles M, et al. Effect

of food on bioavailability of pseudoephedrine and brompheniramine

administered from a gastrointestinal therapeutic system. J Pharm Sci


Rose S, Nelson JF. A continuous long-term injector. Aust J Exp Biol


Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987-91.

Okimoto K, Miyake M, Ohnishi N, Rajewski RA, Uekama K,

Stella VJ. Design and evaluation of an osmotic pump tablet

(OPT) for prednisolone, a poorly water soluble drug, utilizing

(SBE) 7M - β - CD. Pharm Res 1998;15:1562-8.

Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a

model poorly water-soluble drug, prednisolone, from hydroxypropyl

methycellulose matrix tablets using (SBE) 7M -β-cyclodextrin as a

solubilizing agent. J Pharm Sci 2001;90:807-16.

Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric-

membrane tablet coatings for osmotic drug delivery. J Control Release


Thombre AG, DeNoto AR, Gibbes DC. Delivery of glipizide from

asymmetric membrane capsules using encapsulated excipients.

J Control Release 1999;60:333-41.

Chen C, Lee D, Xie J. Controlled release formulation for water insoluble

drugs in which a passageway is formed in situ. US patent 5736159, 1998.

Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic

pump. J Control Release 1985a;1:269-82.

Zentner GM, Rork GS, Himmelstein KJ. Osmotic flow through controlled

porosity films: An approach to delivery of water soluble compounds.

J Control Release 1985b;2:217-29.

Zentner GM, Rork GS, Himmelstein KJ. Controlled porosity osmotic

pump. US Patent 4968507, 1990.

McClelland GA, Zentner GM. Solubility modulated drug delivery system.

US patent 4946686, 1990.

Zentner GM, McClelland GA. Solubility modulated drug delivery device.

US patent 4994273, 1991.

Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic

and diastolic left ventricular function of nebivolol versus atenolol in

patients with uncomplicated essential hypertension. Am J Cardiol


Italian Pharmacopoeia. 10th ed. Rome, Italy: Istituto Poligrafico e Zecca

dello Stato; 1998. p. 610-1.

Caplar V, Mikotic-Mihun Z, Hoffman H, Kuffinec J, Kajfez F. Atenolol,

in Analytical Profiles of Drug Substances. In: Florey K, editor. Vol. 13.

New York: Academic Press; 1984. p. 1-25.

Ficarra R, Ficarra P, DiBella MR, Raneri D, Tommasini S, Calabro ML,

et al. Study of the inclusion complex of atenolol with β-cyclodextrins.

J Pharm Biomed Anal 2000;23:231-6.

Moneghini M, Carcano A, Zingone G, Perissutti B. Studies in dissolution

enhancement of atenolol. Int J Pharm 1998;175:177-83.

Serajuddin AT. Solid dispersion of poorly water-soluble drugs: Early

promises, subsequent problems, and recent breakthroughs. J Pharm

Sci 1999;88:1058-66.

Ayer AD, Theeuwes F. Osmotic system with distribution zone for

dispensing beneficial agent. US Patent 4200098, 1980.

Ramakrishna N, Mishra B. Plastizer effects and comparative evaluation

of cellulose acetate and ethyl cellulose-HPMC combination coating as

semi-permeable membrane for oral osmotic pump of naproixen sodium.

Drug Dev Ind Pharm 2002;28:403-12.

Costa P, Lobo JM. Modeling and comparison of dissolution profiles. Eur

J Pharm Sci 2001;13:123-33.

Verma RK, Kaushal AM, Garg S. Development and evaluation of extended

release formulations of isosorbide mononitrate based on osmotic

technology. Int J Pharm 2003;263:9-24.

Ritschel WA. Biopharmaceutic and pharmacokinetic aspects in the

design of controlled release per-oral drug delivery systems. Drug Dev

Ind Pharm 1989;15:1073-103.

Sheskey P, Sackett G, Maher L, Lentz K, Tolle S, Polli J. Roll compaction

granulation of a controlled-release matrix tablet formulation containing

HPMC: Effect of Process Scale-up on Robustness of Tablets and Predicted

in Vivo Performance. Pharm Technol Tabletting and Granulation Year

book 1999. p. 6-21.

Sheskey P, Pacholke K, Sackett G, Maher L, Polli J. Roll compaction

granulation of a controlled release matrix tablet formulation

containing HPMC: Effect of process scale-up on robustness of tablets,

tablet stability and predicted in vivo performance. Part II. Pharm

Technol 2000;24:30-52.

Wadworth AN, Murdoch D, Brogden RN. Atenolol: A reappraisal of

its pharmacological properties and therapeutic use in cardiovascular

disorders. Drugs 1991;42:468-510.

Jeffers TA, Webster J, Petrie JC, Baker NP. Atenolol once-daily in

hypertension. Br J Pharmacol 1977;4:523-7.

Mehvar R, Gross ME, Kreamer RN. Pharmacokinetics of atenolol

enantiomers in humans and rats. J Pharm Sci 1990;79:881-5.